QUEBEC CITY, March 11 /CNW/ - Medicago Inc. (TSX-V : MDG) (the
"Company"), today announced that Mr. Andy Sheldon, President and CEO, will be
presenting at the Partnering for Global Health Forum 2008 in Washington, DC,
today at 3:30 p.m. EST. Mr. Sheldon will give an overview of the Company's
development of vaccines and manufacturing technologies, and recent preclinical
results of its H5N1 Avian Influenza lead vaccine candidate generated from
plant-made Virus-Like Particles.
Partnering for Global Health Forum 2008 is an international partnering
meeting focused on accelerating the development of medicines for neglected
diseases of the developing world. Leaders from the biopharmaceutical industry,
potential funders and international health experts will discuss the pressing
needs for innovation and explore new avenues for progress and potential
partnerships. The forum is organized by BIO Ventures for Global Health (BVGH)
and the Biotechnology Industry Organization (BIO), and sponsored by the Bill &
Melinda Gates Foundation.
About Medicago Inc.
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market.
Additional information about Medicago is available at www.medicago.com.
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago Inc., Andy Sheldon, President and CEO,
(418) 658-9393; The Equicom Group Inc., Arianna Vanin, Investor Relations,
(514) 844-4680, email@example.com